Renaissance Technologies LLC Makes New Investment in Establishment Labs Holdings Inc. $ESTA

Renaissance Technologies LLC bought a new stake in Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the first quarter, Holdings Channel.com reports. The firm bought 55,800 shares of the company’s stock, valued at approximately $3,168,000.

Other large investors have also modified their holdings of the company. KBC Group NV purchased a new position in shares of Establishment Labs during the 1st quarter worth $28,000. Kestra Advisory Services LLC purchased a new stake in Establishment Labs in the 4th quarter valued at about $47,000. Quarry LP purchased a new stake in Establishment Labs in the 3rd quarter valued at about $34,000. MV Capital Management Inc. acquired a new position in Establishment Labs in the fourth quarter valued at about $146,000. Finally, Osaic Holdings Inc. boosted its stake in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after buying an additional 1,800 shares during the period. Institutional investors and hedge funds own 72.91% of the company’s stock.

Establishment Labs Stock Performance

Shares of Establishment Labs stock opened at $77.42 on Friday. The business has a 50-day moving average of $86.43 and a 200 day moving average of $74.25. Establishment Labs Holdings Inc. has a 12 month low of $33.35 and a 12 month high of $97.59. The stock has a market capitalization of $2.28 billion, a price-to-earnings ratio of -59.10 and a beta of 1.07. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 205.79% and a negative net margin of 15.82%.The business had revenue of $67.54 million for the quarter, compared to analysts’ expectations of $65.79 million. During the same quarter last year, the company earned ($0.57) earnings per share. The firm’s revenue for the quarter was up 31.7% on a year-over-year basis. As a group, sell-side analysts forecast that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on ESTA shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Establishment Labs in a research report on Wednesday, June 24th. Canaccord Genuity Group set a $105.00 price objective on shares of Establishment Labs in a report on Thursday. Mizuho increased their price objective on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. BTIG Research lifted their target price on shares of Establishment Labs from $96.00 to $103.00 and gave the company a “buy” rating in a report on Thursday. Finally, Citigroup boosted their target price on Establishment Labs from $76.00 to $92.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.25.

Trending Headlines about Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: JPMorgan raised its price target on Establishment Labs from $84 to $95 and maintained an Overweight rating, implying substantial upside from the current trading level. Benzinga analyst report
• Positive Sentiment: BTIG increased its price target from $96 to $103 and reiterated a Buy rating, while Needham lifted its target from $86 to $95 and also maintained a Buy rating. These revisions suggest analysts remain optimistic about the company’s growth prospects. The Fly analyst report
• Positive Sentiment: Establishment Labs reported quarterly revenue of $67.54 million, exceeding the $65.79 million analyst estimate and increasing 31.7% year over year. The company also projected 2026 revenue of $269 million to $271 million, above the $267.5 million consensus estimate. Zacks quarterly results report
• Neutral Sentiment: Management indicated that minimally invasive procedures now account for approximately 15% of sales, highlighting potential for longer-term market expansion, but investors may remain focused on the company’s path to profitability. Seeking Alpha revenue outlook report
• Negative Sentiment: The company reported a second-quarter loss of $0.39 per share, wider than the $0.34 expected loss, though the result improved from a $0.57 loss in the year-ago quarter. The earnings miss, continued negative margins, and lack of profitability are likely weighing on the shares. MarketBeat earnings report

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.